Global Prostate Cancer Treatment Market - 2025-2033
Overview
The global prostate cancer treatment market size reached US$ 13.22 billion in 2024 and is expected to reach US$ 28.10 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033.
Prostate cancer, a common type of cancer, originates from the prostate, a small gland responsible for semen production. It is found just below the bladder and is a part of the male reproductive system. Early cases are often found early and grow slowly, with most being cured. Treatment options include surgery, radiation therapy, or monitoring the cancer's growth. If the cancer spreads beyond the prostate, there are still treatments available. However, even if a cure isn't possible, treatments can slow the cancer's growth and prolong life.
Market Dynamics: Drivers & Restraints
Rise in the Incidence of Prostate Cancer
The global prostate cancer treatment market is growing due to its rise in the incidence among men, particularly those aged 50 and above. The growing geriatric population and advancements in diagnostic technologies have led to higher detection rates of the disease, resulting in a demand for various treatment options such as surgery, radiation therapy, hormone therapy, immunotherapy, and targeted therapies. The need for continuous management and long-term care in prostate cancer patients further supports the market expansion, prompting pharmaceutical companies to invest in novel therapeutics.
For instance, according to the Global Cancer Observatory, in 2024, 1.57 million new prostate cancer cases were reported, with a man being diagnosed every 2 minutes, and it has been raised to 1.60 million, and it is expected to rise to around 1.80 million by 2030.
High Cost of Prostate Cancer Therapies
The global prostate cancer treatment market is expanding due to its prevalence among men aged 50 and above, the geriatric population, and advancements in diagnostic technologies. This has led to increased demand for treatments like surgery, radiation therapy, hormone therapy, immunotherapy, and targeted therapies. The need for continuous management and long-term care further supports market expansion, prompting pharmaceutical companies to invest in novel therapeutics. For instance, the American Urological Association's 2023 research reveals an annual cost of $31,427 for metastatic prostate cancer, a rise attributed to the approval of new oral therapies.
Epidemiology Analysis
According to DataM estimates, prostate cancer prevalence worldwide reached 1.57 million cases in 2024, projected to rise to 1.80 million by 2030. This rise is attributed to factors like aging populations, increased awareness, lifestyle changes, and improved survival rates. The need for public health efforts, early detection programs, and advanced treatment options is highlighted, emphasizing the growing burden of prostate cancer on global healthcare systems.
Epidemiology Analysis (By Region)
The incidence of prostate cancer varies among regions. The region with the highest incidence of prostate cancer is the Europe region, accounting for 0.48 billion cases in 2024.
Segment Analysis
The global prostate cancer treatment market is segmented based on stage, therapy, and region.
Therapy:
The radioligand therapy segment is expected to dominate the prostate cancer treatment market with the highest market share.
Radioligand therapy (RLT) is a therapy that uses a radioactive isotope and a ligand to target cancer cell receptors, particularly in prostate cancer. It targets the prostate-specific membrane antigen (PSMA), delivering localized radiation to the tumor, minimizing damage to healthy tissue. This therapy is particularly beneficial for patients with metastatic castration-resistant prostate cancer who have exhausted conventional treatments.
The radioligand therapy segment is expected to grow due to factors such as rising global prevalence, increased awareness, and demand for advanced therapies like targeted laser therapy (RLT). Advancements in diagnostics, strong research pipelines, regulatory approvals, and expanding access to new treatments in emerging markets support market expansion. The aging male population and lifestyle-related risk factors also contribute to the market's growth trajectory.
For instance, in March 2025, Novartis received FDA approval for Pluvicto, a drug used to delay chemotherapy in patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with ARPI therapy and are considered appropriate for this treatment.
Geographical Analysis
North America is expected to hold a significant position in the global prostate cancer treatment market, with the highest market share
North America dominates the global prostate cancer treatment market due to its high prevalence, robust healthcare infrastructure, advanced diagnostic capabilities, and early adoption of innovative therapies. Government and private health insurance programs provide access to costly treatments, while intensive research and development activities, leading pharmaceutical companies, and favorable regulatory frameworks like FDA fast-track approvals support rapid innovation and commercialization of new prostate cancer therapies. This market growth is fueled by a growing patient pool, robust healthcare infrastructure, and favorable regulatory frameworks.
For instance, in March 2025, The U.S. Food and Drug Administration approved 177Lu-PSMA-617 (Pluvicto) for prostate cancer treatment, allowing earlier use of the therapy. This treatment targets PSMA, a protein on cancer cell surfaces, delivering radiation that damages DNA and destroys cancer cells. The therapy is now more accessible to more patients.
Competitive Landscape
Top companies in the prostate cancer treatment market include Astellas Pharma, AstraZeneca, Bayer AG, Dendreon Pharmaceuticals, Exelixis Inc, Ferring B.V, Johnson & Johnson (via Janssen Pharmaceuticals), Pfizer Inc, Sumitomo Pharma Co., Ltd, Novartis and Tolmar, Inc among others.
Key Developments
Target Audience 2024
The global prostate cancer treatment market size reached US$ 13.22 billion in 2024 and is expected to reach US$ 28.10 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033.
Prostate cancer, a common type of cancer, originates from the prostate, a small gland responsible for semen production. It is found just below the bladder and is a part of the male reproductive system. Early cases are often found early and grow slowly, with most being cured. Treatment options include surgery, radiation therapy, or monitoring the cancer's growth. If the cancer spreads beyond the prostate, there are still treatments available. However, even if a cure isn't possible, treatments can slow the cancer's growth and prolong life.
Market Dynamics: Drivers & Restraints
Rise in the Incidence of Prostate Cancer
The global prostate cancer treatment market is growing due to its rise in the incidence among men, particularly those aged 50 and above. The growing geriatric population and advancements in diagnostic technologies have led to higher detection rates of the disease, resulting in a demand for various treatment options such as surgery, radiation therapy, hormone therapy, immunotherapy, and targeted therapies. The need for continuous management and long-term care in prostate cancer patients further supports the market expansion, prompting pharmaceutical companies to invest in novel therapeutics.
For instance, according to the Global Cancer Observatory, in 2024, 1.57 million new prostate cancer cases were reported, with a man being diagnosed every 2 minutes, and it has been raised to 1.60 million, and it is expected to rise to around 1.80 million by 2030.
High Cost of Prostate Cancer Therapies
The global prostate cancer treatment market is expanding due to its prevalence among men aged 50 and above, the geriatric population, and advancements in diagnostic technologies. This has led to increased demand for treatments like surgery, radiation therapy, hormone therapy, immunotherapy, and targeted therapies. The need for continuous management and long-term care further supports market expansion, prompting pharmaceutical companies to invest in novel therapeutics. For instance, the American Urological Association's 2023 research reveals an annual cost of $31,427 for metastatic prostate cancer, a rise attributed to the approval of new oral therapies.
Epidemiology Analysis
According to DataM estimates, prostate cancer prevalence worldwide reached 1.57 million cases in 2024, projected to rise to 1.80 million by 2030. This rise is attributed to factors like aging populations, increased awareness, lifestyle changes, and improved survival rates. The need for public health efforts, early detection programs, and advanced treatment options is highlighted, emphasizing the growing burden of prostate cancer on global healthcare systems.
Epidemiology Analysis (By Region)
The incidence of prostate cancer varies among regions. The region with the highest incidence of prostate cancer is the Europe region, accounting for 0.48 billion cases in 2024.
Segment Analysis
The global prostate cancer treatment market is segmented based on stage, therapy, and region.
Therapy:
The radioligand therapy segment is expected to dominate the prostate cancer treatment market with the highest market share.
Radioligand therapy (RLT) is a therapy that uses a radioactive isotope and a ligand to target cancer cell receptors, particularly in prostate cancer. It targets the prostate-specific membrane antigen (PSMA), delivering localized radiation to the tumor, minimizing damage to healthy tissue. This therapy is particularly beneficial for patients with metastatic castration-resistant prostate cancer who have exhausted conventional treatments.
The radioligand therapy segment is expected to grow due to factors such as rising global prevalence, increased awareness, and demand for advanced therapies like targeted laser therapy (RLT). Advancements in diagnostics, strong research pipelines, regulatory approvals, and expanding access to new treatments in emerging markets support market expansion. The aging male population and lifestyle-related risk factors also contribute to the market's growth trajectory.
For instance, in March 2025, Novartis received FDA approval for Pluvicto, a drug used to delay chemotherapy in patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with ARPI therapy and are considered appropriate for this treatment.
Geographical Analysis
North America is expected to hold a significant position in the global prostate cancer treatment market, with the highest market share
North America dominates the global prostate cancer treatment market due to its high prevalence, robust healthcare infrastructure, advanced diagnostic capabilities, and early adoption of innovative therapies. Government and private health insurance programs provide access to costly treatments, while intensive research and development activities, leading pharmaceutical companies, and favorable regulatory frameworks like FDA fast-track approvals support rapid innovation and commercialization of new prostate cancer therapies. This market growth is fueled by a growing patient pool, robust healthcare infrastructure, and favorable regulatory frameworks.
For instance, in March 2025, The U.S. Food and Drug Administration approved 177Lu-PSMA-617 (Pluvicto) for prostate cancer treatment, allowing earlier use of the therapy. This treatment targets PSMA, a protein on cancer cell surfaces, delivering radiation that damages DNA and destroys cancer cells. The therapy is now more accessible to more patients.
Competitive Landscape
Top companies in the prostate cancer treatment market include Astellas Pharma, AstraZeneca, Bayer AG, Dendreon Pharmaceuticals, Exelixis Inc, Ferring B.V, Johnson & Johnson (via Janssen Pharmaceuticals), Pfizer Inc, Sumitomo Pharma Co., Ltd, Novartis and Tolmar, Inc among others.
Key Developments
- In February 2025, Israeli pharmaceutical company RedHill Biopharma is conducting a Phase II trial to evaluate the combination of opaganib and darolutamide in treating metastatic castrate-resistant prostate cancer (mCRPC). The study, involving 80 male subjects, uses a lipid biomarker test, PCPro, to identify patients with poor prognosis who may benefit from the combination.
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Stage
2.4. Snippet by Therapy Type
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rise in the Incidence of Prostate Cancer
3.1.1.2. Advancements in Treatment Technologies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost of Prostate Cancer Therapies
3.1.2.2. Side Effects and Quality of Life Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Shift Toward Outpatient and Home-Based Care
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. PROSTATE CANCER TREATMENT MARKET, BY STAGE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
5.1.2. Market Attractiveness Index, By Stage
5.2. Stage I*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Stage II
5.4. Stage III
5.5. Stage IV
6. PROSTATE CANCER TREATMENT MARKET, BY THERAPY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Radioligand Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Radiation Therapy
6.3.1. External beam radiation therapy (EBRT)
6.3.2. Intensity modulated radiation therapy (IMRT)
6.3.3. Stereotactic body radiation therapy (SBRT)
6.4. Chemotherapy
6.4.1. Docetaxel
6.4.2. Cabazitaxel
6.4.3. Mitoxantrone
6.4.4. Others
6.5. Hormone therapy
6.5.1. Leuprolide
6.5.2. Goserelin
6.5.3. Triptorelin
6.5.4. Degarelix
6.5.5. Relugolix
6.6. Targeted therapy
6.6.1. Rucaparib
6.6.2. Olaparib
6.6.3. Talazoparib
6.6.4. Niraparib plus abiraterone
6.7. Immunotherapy
6.7.1. Dostarlimab
6.7.2. Pembrolizumab
6.7.3. Sipuleucel-T
6.8. Surgery
6.8.1. Radical prostatectomy
6.8.2. Transurethral resection of the prostate (TURP)
6.8.3. Orchiectomy
7. PROSTATE CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Astellas Pharma*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue’s
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. AstraZeneca
9.3. Bayer AG
9.4. Dendreon Pharmaceuticals
9.5. Exelixis Inc
9.6. Ferring B.V
9.7. Johnson & Johnson (via Janssen Pharmaceuticals)
9.8. Pfizer Inc
9.9. Sumitomo Pharma Co., Ltd
9.10. Novartis
9.11. Tolmar, Inc
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Stage
2.4. Snippet by Therapy Type
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rise in the Incidence of Prostate Cancer
3.1.1.2. Advancements in Treatment Technologies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Cost of Prostate Cancer Therapies
3.1.2.2. Side Effects and Quality of Life Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Shift Toward Outpatient and Home-Based Care
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. PROSTATE CANCER TREATMENT MARKET, BY STAGE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
5.1.2. Market Attractiveness Index, By Stage
5.2. Stage I*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Stage II
5.4. Stage III
5.5. Stage IV
6. PROSTATE CANCER TREATMENT MARKET, BY THERAPY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Radioligand Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Radiation Therapy
6.3.1. External beam radiation therapy (EBRT)
6.3.2. Intensity modulated radiation therapy (IMRT)
6.3.3. Stereotactic body radiation therapy (SBRT)
6.4. Chemotherapy
6.4.1. Docetaxel
6.4.2. Cabazitaxel
6.4.3. Mitoxantrone
6.4.4. Others
6.5. Hormone therapy
6.5.1. Leuprolide
6.5.2. Goserelin
6.5.3. Triptorelin
6.5.4. Degarelix
6.5.5. Relugolix
6.6. Targeted therapy
6.6.1. Rucaparib
6.6.2. Olaparib
6.6.3. Talazoparib
6.6.4. Niraparib plus abiraterone
6.7. Immunotherapy
6.7.1. Dostarlimab
6.7.2. Pembrolizumab
6.7.3. Sipuleucel-T
6.8. Surgery
6.8.1. Radical prostatectomy
6.8.2. Transurethral resection of the prostate (TURP)
6.8.3. Orchiectomy
7. PROSTATE CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Astellas Pharma*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue’s
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. AstraZeneca
9.3. Bayer AG
9.4. Dendreon Pharmaceuticals
9.5. Exelixis Inc
9.6. Ferring B.V
9.7. Johnson & Johnson (via Janssen Pharmaceuticals)
9.8. Pfizer Inc
9.9. Sumitomo Pharma Co., Ltd
9.10. Novartis
9.11. Tolmar, Inc
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Prostate Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 6 Global Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 8 Global Prostate Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Prostate Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 11 North America Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 12 North America Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 South America Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 14 South America Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 15 South America Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Europe Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 17 Europe Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 18 Europe Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Astellas Pharma: Overview
Table 26 Astellas Pharma: Product Portfolio
Table 27 Astellas Pharma: Key Developments
Table 28 AstraZeneca: Overview
Table 29 AstraZeneca: Product Portfolio
Table 30 AstraZeneca: Key Developments
Table 31 Bayer AG: Overview
Table 32 Bayer AG: Product Portfolio
Table 33 Bayer AG: Key Developments
Table 34 Dendreon Pharmaceuticals: Overview
Table 35 Dendreon Pharmaceuticals: Product Portfolio
Table 36 Dendreon Pharmaceuticals: Key Developments
Table 37 Exelixis Inc: Overview
Table 38 Exelixis Inc: Product Portfolio
Table 39 Exelixis Inc: Key Developments
Table 40 Ferring B.V: Overview
Table 41 Ferring B.V: Product Portfolio
Table 42 Ferring B.V: Key Developments
Table 43 Johnson & Johnson (via Janssen Pharmaceuticals): Overview
Table 44 Johnson & Johnson (via Janssen Pharmaceuticals): Product Portfolio
Table 45 Johnson & Johnson (via Janssen Pharmaceuticals): Key Developments
Table 46 Pfizer Inc: Overview
Table 47 Pfizer Inc: Product Portfolio
Table 48 Pfizer Inc: Key Developments
Table 49 Sumitomo Pharma Co., Ltd: Overview
Table 50 Sumitomo Pharma Co., Ltd: Product Portfolio
Table 51 Sumitomo Pharma Co., Ltd: Key Developments
Table 52 Novartis: Overview
Table 53 Novartis: Product Portfolio
Table 54 Novartis: Key Developments
Table 55 Tolmar, Inc: Overview
Table 56 Tolmar, Inc: Product Portfolio
Table 57 Tolmar, Inc: Key Developments
Table 1 Global Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Prostate Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Prostate Cancer Treatment Market Value, By Stage, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 6 Global Prostate Cancer Treatment Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 8 Global Prostate Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Prostate Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 11 North America Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 12 North America Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 South America Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 14 South America Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 15 South America Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Europe Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 17 Europe Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 18 Europe Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Prostate Cancer Treatment Market Value, By Stage, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Prostate Cancer Treatment Market Value, By Therapy Type, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Prostate Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Astellas Pharma: Overview
Table 26 Astellas Pharma: Product Portfolio
Table 27 Astellas Pharma: Key Developments
Table 28 AstraZeneca: Overview
Table 29 AstraZeneca: Product Portfolio
Table 30 AstraZeneca: Key Developments
Table 31 Bayer AG: Overview
Table 32 Bayer AG: Product Portfolio
Table 33 Bayer AG: Key Developments
Table 34 Dendreon Pharmaceuticals: Overview
Table 35 Dendreon Pharmaceuticals: Product Portfolio
Table 36 Dendreon Pharmaceuticals: Key Developments
Table 37 Exelixis Inc: Overview
Table 38 Exelixis Inc: Product Portfolio
Table 39 Exelixis Inc: Key Developments
Table 40 Ferring B.V: Overview
Table 41 Ferring B.V: Product Portfolio
Table 42 Ferring B.V: Key Developments
Table 43 Johnson & Johnson (via Janssen Pharmaceuticals): Overview
Table 44 Johnson & Johnson (via Janssen Pharmaceuticals): Product Portfolio
Table 45 Johnson & Johnson (via Janssen Pharmaceuticals): Key Developments
Table 46 Pfizer Inc: Overview
Table 47 Pfizer Inc: Product Portfolio
Table 48 Pfizer Inc: Key Developments
Table 49 Sumitomo Pharma Co., Ltd: Overview
Table 50 Sumitomo Pharma Co., Ltd: Product Portfolio
Table 51 Sumitomo Pharma Co., Ltd: Key Developments
Table 52 Novartis: Overview
Table 53 Novartis: Product Portfolio
Table 54 Novartis: Key Developments
Table 55 Tolmar, Inc: Overview
Table 56 Tolmar, Inc: Product Portfolio
Table 57 Tolmar, Inc: Key Developments
LIST OF FIGURES
Figure 1 Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 3 Global Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 4 Global Prostate Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Prostate Cancer Treatment Market Y-o-Y Growth, By Stage, 2023-2033 (%)
Figure 6 Stage I Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 7 Stage II Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Stage III Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Stage IV Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Prostate Cancer Treatment Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 11 Radioligand Therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Radiation Therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Chemotherapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Hormone therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Targeted therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Immunotherapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Surgery Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Prostate Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 19 North America Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 North America Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 21 North America Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 22 North America Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 23 South America Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 24 South America Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 25 South America Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 26 South America Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 29 Europe Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 30 Europe Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 31 Asia-Pacific Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 32 Asia-Pacific Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 33 Asia-Pacific Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 35 Middle East and Africa Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 36 Middle East and Africa Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 37 Middle East and Africa Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 38 Astellas Pharma: Financials
Figure 39 AstraZeneca: Financials
Figure 40 Bayer AG: Financials
Figure 41 Dendreon Pharmaceuticals: Financials
Figure 42 Exelixis Inc: Financials
Figure 43 Ferring B.V: Financials
Figure 44 Johnson & Johnson (via Janssen Pharmaceuticals): Financials
Figure 45 Pfizer Inc: Financials
Figure 46 Sumitomo Pharma Co., Ltd: Financials
Figure 47 Novartis: Financials
Figure 48 Tolmar, Inc: Financials
Figure 1 Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 3 Global Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 4 Global Prostate Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Prostate Cancer Treatment Market Y-o-Y Growth, By Stage, 2023-2033 (%)
Figure 6 Stage I Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 7 Stage II Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Stage III Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Stage IV Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Prostate Cancer Treatment Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 11 Radioligand Therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Radiation Therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Chemotherapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Hormone therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Targeted therapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Immunotherapy Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Surgery Therapy Type in Global Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Prostate Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 19 North America Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 North America Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 21 North America Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 22 North America Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 23 South America Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 24 South America Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 25 South America Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 26 South America Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 29 Europe Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 30 Europe Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 31 Asia-Pacific Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 32 Asia-Pacific Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 33 Asia-Pacific Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Prostate Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 35 Middle East and Africa Prostate Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 36 Middle East and Africa Prostate Cancer Treatment Market Share, By Stage, 2024 & 2033 (%)
Figure 37 Middle East and Africa Prostate Cancer Treatment Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 38 Astellas Pharma: Financials
Figure 39 AstraZeneca: Financials
Figure 40 Bayer AG: Financials
Figure 41 Dendreon Pharmaceuticals: Financials
Figure 42 Exelixis Inc: Financials
Figure 43 Ferring B.V: Financials
Figure 44 Johnson & Johnson (via Janssen Pharmaceuticals): Financials
Figure 45 Pfizer Inc: Financials
Figure 46 Sumitomo Pharma Co., Ltd: Financials
Figure 47 Novartis: Financials
Figure 48 Tolmar, Inc: Financials
